Surrozen (SRZN) Registration Filing summary

Company overview and business model

• Focuses on discovering and developing biologic drug candidates to selectively modulate the Wnt pathway, targeting tissue repair with a current emphasis on ophthalmology.

• Leverages proprietary platform technologies to design tissue-targeted therapeutics for a range of severe diseases affecting organs such as the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and CNS.

• Lead product candidates are multi-specific, antibody-based therapeutics that mimic naturally occurring Wnt proteins.

• Strategy centers on advancing tissue-selective Wnt candidates into clinical development for indications with high unmet need, with ophthalmology as a key area.

Use of proceeds and capital allocation

• Net proceeds from securities sales are intended for working capital and general corporate purposes, including research and development, administrative matters, business opportunities, and capital expenditures.

• May allocate a portion of proceeds for strategic investments in complementary businesses, services, products, or technologies, though no current agreements exist.

Risk factors and disclosures

• Investment involves a high degree of risk, including business, competitive, regulatory, and economic uncertainties that could materially affect future results.

• Risks are detailed in the prospectus, annual and quarterly reports, and may include factors such as clinical trial outcomes, capital needs, competition, and macroeconomic conditions.

• Past financial performance is not indicative of future results; historical trends should not be used to anticipate future outcomes.